12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lyxumia lixisenatide: Additional Phase III data

Additional data from the double-blind, international Phase III GetGoal-P trial in 484 Type II diabetics inadequately controlled with pioglitazone showed that once-daily 20 µg Lyxumia as an add-on to pioglitazone with or without metformin significantly reduced FPG from baseline to week 24 vs. placebo plus pioglitazone with or without metformin (1.16 vs. 0.32 mmol/L, p<0.0001). Additionally, a significantly greater proportion of patients receiving Lyxumia achieved an HbA1c of <7% at week 24...

Read the full 336 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >